样式: 排序: IF: - GO 导出 标记为已读
-
Authors' Reply: Eculizumab Seems to be a Life Saver Even in Shiga Toxin-Related Hemolytic Uremic Syndrome J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Garnier, Arnaud
No abstract available
-
Prioritizing Skills for Optimal Peritoneal Dialysis Care: A Focus Beyond Specialty J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Sahutoglu, Tuncay
No abstract available
-
Assessment of Novel Therapeutics to Improve Access to Transplantation for Highly Sensitized Patients in a Shifting Clinical Landscape J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Lan, James H.
No abstract available
-
Adenine Nucleotide Translocators Control Kidney Metabolism and Lipid Handling J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Sugahara, Sho, Brooks, Craig R.
No abstract available
-
-
Authors' Reply: Prioritizing Skills for Optimal Peritoneal Dialysis Care: A Focus Beyond Specialty J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Ku, Elaine, McCulloch, Charles E., Copeland, Timothy P., Johansen, Kirsten L.
No abstract available
-
Eculizumab Seems to be a Life Saver Even in Shiga Toxin–Related Hemolytic–Uremic Syndrome J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Pottokaran, Jaicy
No abstract available
-
-
Improving Community Care of Individuals with CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-02-01 Lim, Cynthia Ciwei, Tay, Wei Yi
No abstract available
-
Authors' Reply: Platelet Count, Platelet Volume and CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-02-01 Kore, Rajshekhar, Jadvani, Dharmik, Arthur, John M., Jain, Nishank
No abstract available
-
-
Platelet Count, Platelet Volume, and CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-02-01 Daungsupawong, Hinpetch, Wiwanitkit, Viroj
No abstract available
-
-
Prophylactic Phosphate Restriction: A Strategy to Mitigate AKI-Associated Complications J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-26 Ben-Dov, Iddo Z., Potruch, Assaf, Abbasi, Momen
No abstract available
-
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-23 Navdeep Tangri, Vandana S. Mathur, David A. Bushinsky, Gerrit Klaerner, Elizabeth Li, Dawn Parsell, Yuri Stasiv, Michael Walker, Donald E. Wesson, David C. Wheeler, Vlado Perkovic, Lesley A. Inker
CKD study randomized 1480 individuals with CKD and metabolic acidosis, across 320 sites to placebo or veverimer (a novel hydrochloric acid binder). The findings did not demonstrate the efficacy of veverimer in slowing CKD progression, but the difference in serum bicarbonate between placebo and drug arms was only approximately 1 mEq/L. Veverimer was safe and well tolerated. Background Metabolic acidosis
-
Role of Age and Competing Risk of Death in the Racial Disparity of Kidney Failure Incidence after Onset of CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-23 Guofen Yan, Robert Nee, Julia J. Scialla, Tom Greene, Wei Yu, Fei Heng, Alfred K. Cheung, Keith C. Norris
rans had a 2.5-fold higher cumulative incidence of kidney failure, compared with White veterans, in any follow-up period from CKD onset. This disparity resulted from a combination of higher hazards of progression to kidney failure and lower hazards of competing-risk death in Black veterans. Both, in turn, were largely explained by the younger age at CKD onset in Black veterans, underscoring an urgent
-
Renal Mitochondrial ATP Transporter Ablation Ameliorates Obesity-Induced CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-11 Anna Permyakova, Sharleen Hamad, Liad Hinden, Saja Baraghithy, Aviram Kogot-Levin, Omri Yosef, Ori Shalev, Manish Kumar Tripathi, Haitham Amal, Abhishek Basu, Muhammad Arif, Resat Cinar, George Kunos, Michael Berger, Gil Leibowitz, Joseph Tam
y acid oxidation to aerobic glycolysis, resulting in mitochondrial protection, cellular survival, and preservation of renal function. These findings provide new insights into the underlying mechanisms of obesity-induced CKD and have the potential to be translated toward the development of targeted therapeutic strategies for this debilitating condition. Background The impairment in ATP production and
-
Advancing Clinical Care through ASN Kidney Health Guidance J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-08 Sarah L. Sampsel, Deidra C. Crews
An abstract is unavailable.
-
Lipid Management and Interactions with Immunosuppressants in Patients Undergoing Kidney Transplant: Opinions and Prospects J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-01 Li, Yanqin, Luo, Fan, Gao, Qi, Su, Licong
No abstract available
-
-
Authors' Reply: Lipid Management and Interactions with Immunosuppressants in Kidney Transplant Patients: Some Opinions and Prospects J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-01 Bae, Sunjae, McAdams-DeMarco, Mara A.
No abstract available
-
Phosphate Restriction Prevents Metabolic Acidosis and Curbs Rise in FGF23 and Mortality in Murine Folic Acid–Induced AKI J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-04 Ahmad Kamal Hamid, Eva Maria Pastor Arroyo, Charlotte Calvet, Timothy D. Hewitson, Maria Lavinia Muscalu, Udo Schnitzbauer, Edward R. Smith, Carsten Alexander Wagner, Daniela Egli-Spichtig
that dietary Pi restriction markedly diminished the early rise in plasma FGF23 and prevented the rise in plasma Pi, parathyroid hormone, and calcitriol in mice with folic acid–induced AKI (FA-AKI). Furthermore, the study provides evidence for Pi-sensitive osseous Fgf23 mRNA expression and reveals that Pi restriction mitigated calciprotein particles (CPPs) formation, inflammation, acidosis, cardiac
-
-
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-26 Vincenti, Flavio, Bestard, Oriol, Brar, Amarpali, Cruzado, Josep M., Seron, Daniel, Gaber, A. Osama, Ali, Nicole, Tambur, Anat R., Lee, Helen, Abbadessa, Giovanni, Paul, Jo-Anne, Dudek, Markus, Siegel, Ruby J., Torija, Alba, Semiond, Dorothée, Lépine, Lucie, Ternes, Nils, Montgomery, Robert A., Stegall, Mark
Significance Statement There is no standardized desensitization regimen for kidney transplant candidates. CD38, expressed by plasma cells, could be targeted for desensitization to deplete plasma cells producing alloantibodies and donor-specific antibodies. Few studies and case reports are available regarding the use of CD38 antibodies for desensitization in patients awaiting kidney transplant. This
-
SGLT2 Inhibition and Tubular Sodium Handling J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-22 Biff F. Palmer, Deborah J. Clegg
An abstract is unavailable.
-
Are Observational Reports on the Association of Dialysate Sodium with Mortality Enough to Change Practice? Perspective from the RESOLVE Study Team J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-14 Brendan Smyth, Rathika Krishnasamy, Meg Jardine, on behalf of the RESOLVE Study Global Team
An abstract is unavailable.
-
Predicting Outcomes in Nephrology: Lots of Tools, Limited Uptake: How Do We Move Forward? J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-13 Adeera Levin
An abstract is unavailable.
-
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3–5: An Analysis of a Randomized Trial (RESCUE) J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-13 Pablo E. Pergola, Michael Davidson, Camilla Jensen, Amir A. Mohseni Zonoozi, Dominic S. Raj, Philip Andreas Schytz, Katherine R. Tuttle, Vlado Perkovic
ith inflammation and hyporesponsiveness to treatment with erythropoiesis-stimulating agents. This exploratory analysis of the RESCUE clinical trial found that among patients with CKD stage 3–5 and systemic inflammation, ziltivekimab treatment significantly increased hemoglobin (Hb) levels after 12 weeks compared with placebo. Ziltivekimab was also associated with significant increases in serum iron
-
Prognostic Models in Nephrology: Where Do We Stand and Where Do We Go from Here? Mapping Out the Evidence in a Scoping Review J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-12 Jet Milders, Chava L. Ramspek, Roemer J. Janse, Willem Jan W. Bos, Joris I. Rotmans, Friedo W. Dekker, Merel van Diepen
field of prognostic models for kidney patients and provide directions on how to proceed from here. We performed a scoping review of studies developing, validating, or updating a prognostic model for patients with CKD. We searched all published models in PubMed and Embase and report predicted outcomes, methodological quality, and validation and/or updating efforts. We found 602 studies, of which 30
-
The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-12 Sebastian Bate, Dominic McGovern, Francesca Costigliolo, Pek Ghe Tan, Vojtech Kratky, Jennifer Scott, Gavin B. Chapman, Nina Brown, Lauren Floyd, Benoit Brilland, Eduardo Martín-Nares, Mehmet Fethullah Aydın, Duha Ilyas, Arslan Butt, Eithne Nic an Riogh, Marek Kollar, Jennifer S. Lees, Abdülmecit Yildiz, Andrea Hinojosa-Azaola, Ajay Dhaygude, Stephen A. Roberts, Avi Rosenberg, Thorsten Wiech, Charles
(Harrell's C=0.779). In the development cohort of 959 patients, no additional parameters aiding the tool were detected, but replacing the GFR with creatinine identified an additional cutoff. The parameter interstitial fibrosis and tubular atrophy was modified to allow wider access, risk points were reweighted, and a fourth risk group was created, improving predictive ability (C=0.831). In the validation
-
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-12 Kaitlin J. Mayne, Natalie Staplin, David F. Keane, Christoph Wanner, Susanne Brenner, Vladimir Cejka, Johannes Stegbauer, Parminder K. Judge, David Preiss, Jonathan Emberson, Daniele Trinca, Rejive Dayanandan, Ryonfa Lee, John Nolan, Akiko Omata, Jennifer B. Green, David Z.I. Cherney, Lai Seong Hooi, Roberto Pontremoli, Katherine R. Tuttle, Jennifer S. Lees, Patrick B. Mark, Simon J. Davies, Sibylle
tion had clinically significant levels of bioimpedance-derived “Fluid Overload” at recruitment. Empagliflozin induced a prompt and sustained reduction in “Fluid Overload,” irrespective of sex, diabetes, and baseline N-terminal pro B-type natriuretic peptide or eGFR. No significant effect on bioimpedance-derived fat mass was observed. The effects of SGLT2 inhibitors on body water may be one of the contributing
-
Matrix Metalloproteinase-7 in Urinary Extracellular Vesicles Identifies Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-11 van Heugten, Martijn H., Blijdorp, Charles J., Arjune, Sita, van Willigenburg, Hester, Bezstarosti, Karel, Demmers, Jeroen A.A., Musterd-Bhaggoe, Usha, Meijer, Esther, Gansevoort, Ron T., Zietse, Robert, Hayat, Sikander, Kramann, Rafael, Müller, Roman-Ulrich, Salih, Mahdi, Hoorn, Ewout J. On behalf of the DIPAK Consortium
Significance Statement There is an unmet need for biomarkers of disease progression in autosomal dominant polycystic kidney disease (ADPKD). This study investigated urinary extracellular vesicles (uEVs) as a source of such biomarkers. Proteomic analysis of uEVs identified matrix metalloproteinase 7 (MMP-7) as a biomarker predictive of rapid disease progression. In validation studies, MMP-7 was predictive
-
Heterogeneous Treatment Effects of Intensive Glycemic Control on Kidney Microvascular Outcomes and Mortality in ACCORD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-11 Vivek Charu, Jane W. Liang, Glenn M. Chertow, June Li, Maria E. Montez-Rath, Pascal Geldsetzer, Ian H. de Boer, Lu Tian, Manjula Kurella Tamura
al, considering three outcomes of interest—a composite kidney outcome (driven by macroalbuminuria), all-cause mortality, and first assisted hypoglycemic event. We demonstrate that the effects of intensive glycemic control vary with risk of kidney failure, as predicted by the kidney failure risk equation (KFRE). Participants at highest risk of kidney failure gain the largest absolute kidney benefit
-
Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-11 Veena S. Rao, Juan B. Ivey-Miranda, Zachary L. Cox, Julieta Moreno-Villagomez, Christopher Maulion, Lavanya Bellumkonda, John Chang, M. Paul Field, Daniel R. Wiederin, Javed Butler, Sean P. Collins, Jeffrey M. Turner, F. Perry Wilson, Silvio E. Inzucchi, Christopher S. Wilcox, David H. Ellison, Jeffrey M. Testani
reabsorption), a magnitude out of proportion to that expected with only inhibition of sodium–glucose cotransporter-2. This finding was not driven by an “osmotic diuretic” effect; however, several parameters changed in a manner consistent with inhibition of the sodium–hydrogen exchanger 3. The large changes in proximal tubular handling were acutely buffered by increased reabsorption in both the loop
-
Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I2 Receptor J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-08 Jing Li, Yi Guan, Yunyu Xu, Yingxue Cao, Qionghong Xie, Raymond C. Harris, Matthew D. Breyer, Limin Lu, Chuan-Ming Hao
f a PGI2 analog or selective PTGIR agonist after the acute injury ameliorated renal fibrosis. Our findings provide new insights into the role of PGI2 in kidney biology and suggest that targeting PGI2/PTGIR may be a potential therapeutic strategy for CKD. Background Prostanoids have been demonstrated to be important modulators to maintain tissue homeostasis in response to physiologic or pathophysiologic
-
Prognostic Biomarkers in Kidney Transplantation: A Systematic Review and Critical Appraisal J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-06 Marc Raynaud, Solaf Al-Awadhi, Kevin Louis, Huanxi Zhang, Xiaojun Su, Valentin Goutaudier, Jiali Wang, Zeynep Demir, Yongcheng Wei, Agathe Truchot, Antoine Bouquegneau, Arnaud Del Bello, Élodie Bailly, Yannis Lombardi, Mehdi Maanaoui, Alessia Giarraputo, Sofia Naser, Gillian Divard, Olivier Aubert, Mohammad Hassan Murad, Changxi Wang, Longshan Liu, Oriol Bestard, Maarten Naesens, John J. Friedewald
expert reviewers, the authors have identified all prognostic kidney transplant biomarkers and showed overall suboptimal study designs, methods, results, interpretation, reproducible research standards, and transparency. The authors also demonstrated for the first time that the limited number of studies challenged the added value of their candidate biomarkers against standard-of-care routine patient
-
Of Peritoneal Dialysis Access and Home Dialysis Accessibility J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-06 Jeffrey Perl, Isaac Teitelbaum, Robert R. Quinn
An abstract is unavailable.
-
Morphometric Approach to Different Nephron Segments J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-01 Sasaki, Takaya, Tsuboi, Nobuo
No abstract available
-
Dicarboxylic Acid Dietary Supplementation Protects against AKI J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-04 Anne C. Silva Barbosa, Katherine E. Pfister, Takuto Chiba, Joanna Bons, Jacob P. Rose, Jordan B. Burton, Christina D. King, Amy O'Broin, Victoria Young, Bob Zhang, Bharathi Sivakama, Alexandra V. Schmidt, Rebecca Uhlean, Akira Oda, Birgit Schilling, Eric S. Goetzman, Sunder Sims-Lucas
ch is responsible for breaking down fats, without adversely affecting mitochondrial function. DC8 is not only affordable and easy to administer but also effective. These encouraging findings suggest that DC8 could potentially be used to assist patients who are at risk of experiencing this type of kidney damage. Background Proximal tubules are rich in peroxisomes, which are damaged during AKI. Previous
-
Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-04 Kalani L. Raphael, Ronit Katz, Brett Larive, Cynthia Kendrick, Tamara Isakova, Stuart Sprague, Myles Wolf, Dominic S. Raj, Linda F. Fried, Jennifer Gassman, Andy Hoofnagle, Alfred K. Cheung, Joachim H. Ix
er markers and other hormones related to bone health in individuals with CKD who have normal to slightly reduced total CO2 (20–28 mEq/L). Sodium bicarbonate increased serum levels of α-klotho but had no significant effect on other bone health markers, including intact fibroblast growth factor-23 (iFGF-23), intact parathyroid hormone (iPTH), and bone-specific alkaline phosphatase (B-SAP). Further study
-
-
Authors' Reply: Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation? J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-01 Perico, Norberto, Griffin, Matthew D., Casiraghi, Federica, Remuzzi, Giuseppe
No abstract available
-
-
Authors' Reply: Morphometric Approach to Different Nephron Segments J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-01 Denic, Aleksandar, Fnu, Aperna, Mahesh, Kumar, Rule, Andrew D.
No abstract available
-
Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation? J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-01 Chen, Jun-Zhang, Liang, Bo
No abstract available
-
Does Serum Creatinine Reflect Muscle Mass in Patients with Kidney Failure? J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-28 Sankar D. Navaneethan, William E. Mitch
An abstract is unavailable.
-
The B1 H+-ATPase (Atp6v1b1) Subunit in Non–Type A Intercalated Cells is Required for Driving Pendrin Activity and the Renal Defense Against Alkalosis J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-22 Soline Bourgeois, Jana Kovacikova, Milica Bugarski, Carla Bettoni, Nicole Gehring, Andrew Hall, Carsten A. Wagner
lkali-secreting non–type A ICs where its function is incompletely understood. We demonstrate in Atp6v1b1 knock out mice that the B1 subunit is critical for the renal response to defend against alkalosis during an alkali load or chronic furosemide treatment. These findings highlight the importance of non–type A ICs in maintaining acid–base balance in response to metabolic challenges or commonly used
-
Effect of Dialysate and Plasma Sodium on Mortality in a Global Historical Hemodialysis Cohort J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-15 Pinter, Jule, Smyth, Brendan, Stuard, Stefano, Jardine, Meg, Wanner, Christoph, Rossignol, Patrick, Wheeler, David C., Marshall, Mark R., Canaud, Bernard, Genser, Bernd
Significance Statement This large observational cohort study aimed to investigate the relationship between dialysate and plasma sodium concentrations and mortality among maintenance hemodialysis patients. Using a large multinational cohort of 68,196 patients, we found that lower dialysate sodium concentrations (≤138 mmol/L) were independently associated with higher mortality compared with higher dialysate
-
Impact of Dialysate and Plasma Sodium on Mortality in a Global Historical Hemodialysis Cohort. J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-15 Jule Pinter,Brendan Smyth,Stefano Stuard,Meg Jardine,Christoph Wanner,Patrick Rossignol,David C Wheeler,Mark R Marshall,Bernard Canaud,Bernd Genser
BACKGROUND Excess mortality in hemodialysis patients is largely due to cardiovascular disease and is associated with abnormal fluid status and plasma sodium concentrations. Ultrafiltration facilitates the removal of fluid and sodium, whereas diffusive exchange of sodium plays a pivotal role in sodium removal and tonicity adjustment. Lower dialysate sodium may increase sodium removal at the expense
-
Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced AKI J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-14 Pushpan, Chithra K., Kresock, Daniel F., Ingersoll, Matthew A., Lutze, Richard D., Keirns, Darby L., Hunter, William J., Bashir, Khalid, Teitz, Tal
Significance Statement To combat both untoward effects of nephrotoxicity and ototoxicity in cisplatin-treated patients, two potential therapeutic oral anticancer drugs AZD5438 and dabrafenib, a phase-2 clinical trial protein kinase CDK2 inhibitor and an US Food and Drug Administration–approved drug BRAF inhibitor, respectively, were tested in an established mouse AKI model. Both drugs have previously
-
Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced Acute Kidney Injury. J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-14 Chithra K Pushpan,Daniel F Kresock,Matthew A Ingersoll,Richard D Lutze,Darby L Keirns,William J Hunter,Khalid Bashir,Tal Teitz
BACKGROUND Cisplatin is an effective chemotherapy agent for a wide variety of solid tumors, but its use is dose-limited by serious side effects including acute kidney injury (AKI) and hearing loss. There are no FDA-approved drugs to treat both side effects. Recently, two anti-cancer oral drugs, AZD5438 and dabrafenib, were identified as protective against cisplatin-induced hearing loss in mice. We
-
Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-13 Ivan Weisser, Kara Eckberg, Stephen D'Amico, Daniel Buttram, Karam Aboudehen
ey disease (ADPKD) has been understudied. This study provides evidence implicating a lncRNA in the pathogenesis of ADPKD. We report that Hoxb3os is downregulated in ADPKD and regulates mammalian target of rapamycin (mTOR)/Akt pathway in the in vivo mouse kidney. Ablating the expression of Hoxb3os in mouse polycystic kidney disease (PKD) activated mTOR complex 2 (mTORC2) signaling and exacerbated the
-
The COVID-19 Pandemic: A Special Challenge for the Journal's Editors J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-01 Kronbichler, Andreas, Gregg, L. Parker, Bargman, Joanne M.
No abstract available
-
The COVID-19 Pandemic: A Special Challenge for the Journal's Editors. J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-01 Andreas Kronbichler,L Parker Gregg,Joanne M Bargman
-
Integer Cystatin C Values: Impact on Discordance Group Assignment and Accuracy of GFR-Estimating Equations J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-01 Groothof, Dion, Shehab, Naser B.N., Erler, Nicole S., Bakker, Stephan J.L.
No abstract available
-
Authors' Reply: Integer Cystatin C Values: Impact on Discordance Group Assignment and Accuracy of GFR-Estimating Equations J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-11-01 Fu, Edouard L., Levey, Andrew S., Inker, Lesley A., Carrero, Juan-Jesus
No abstract available
-
-
-
It Takes a Village J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-10-30 Josephine P. Briggs
An abstract is unavailable.
-
Navigating the Omics Frontier: Challenges, Opportunities, and the Future of Precision Nephrology J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-10-30 Markus M. Rinschen, Mark A. Knepper
An abstract is unavailable.